Insider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Sells 55,000 Shares of Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $15.77, for a total value of $867,350.00. Following the completion of the transaction, the chief executive officer now directly owns 429,398 shares in the company, valued at $6,771,606.46. This trade represents a 11.35 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Saurabh Saha also recently made the following trade(s):

• On Friday, December 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $17.44, for a total transaction of $959,200.00.
• On Friday, December 6th, Saurabh Saha sold 87,496 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $18.46, for a total transaction of $1,615,176.16.
• On Monday, November 25th, Saurabh Saha sold 299 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $18.23, for a total transaction of $5,450.77.
• On Wednesday, November 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $16.89, for a total value of $928,950.00.
• On Friday, November 22nd, Saurabh Saha sold 1,671 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $18.24, for a total value of $30,479.04.

Centessa Pharmaceuticals Stock Up 1.3 %

Centessa Pharmaceuticals stock traded up $0.22 on Wednesday, hitting $16.68. 165,115 shares of the stock traded hands, compared to its average volume of 506,798. The business’s fifty day simple moving average is $16.83 and its 200 day simple moving average is $14.77. The firm has a market cap of $2.20 billion, a P/E ratio of -10.90 and a beta of 1.53. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. Centessa Pharmaceuticals plc has a 1 year low of $7.38 and a 1 year high of $18.97.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.05. As a group, sell-side analysts forecast that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CNTA. Jane Street Group LLC purchased a new position in shares of Centessa Pharmaceuticals in the 3rd quarter worth about $2,834,000. Wellington Management Group LLP purchased a new stake in shares of Centessa Pharmaceuticals during the third quarter valued at approximately $1,609,000. Nantahala Capital Management LLC purchased a new position in Centessa Pharmaceuticals in the 2nd quarter worth approximately $4,064,000. Ally Bridge Group NY LLC bought a new position in Centessa Pharmaceuticals in the 3rd quarter valued at approximately $4,951,000. Finally, State Street Corp purchased a new stake in Centessa Pharmaceuticals during the 3rd quarter valued at $777,000. Institutional investors own 82.01% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Guggenheim raised their price target on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. TD Cowen began coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating for the company. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $25.83.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.